Sun Yingjia, Ai Xinghao, Shen Shengping, Gu Linping, Lu Shun
Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Patient Prefer Adherence. 2015 Aug 12;9:1165-9. doi: 10.2147/PPA.S86605. eCollection 2015.
To detect and analyze 13 cytokines that may be related to bone metastasis in the serum of non-small-cell lung cancer (NSCLC) patients with bone metastases and NSCLC patients with non-bone metastases.
The Luminex LiquiChip system was used to detect the concentration of 13 cytokines that may be related to bone metastasis in the serum of 30 NSCLC patients with bone metastases and 30 with non-bone metastases.
The concentration of insulin-like growth factor binding protein-3 (IGFBP-3) in the serum of NSCLC patients with bone metastases was obviously higher than in non-bone metastasis patients (P=0.014). The serum concentration of other cytokines showed no significant difference (P>0.05) between the two groups. The concentration of IGFBP-3 in the serum of the bone metastasis group was positively correlated to VEGF concentration (r=0.804, P=0.009) and monocyte chemotactic protein 1 (MCP-1) concentration (r=0.785, P=0.012), but had no correlation to other factors (P>0.05). No correlation was found between serum concentrations of cytokines in bone metastasis. Concentration of IGFBP-3 in the serum of bone metastasis patients was positively correlated to the presence or absence of pain at diagnosis (r=0.701, P=0.036) and performance status (PS) score (r=0.670, P=0.048), and correlated with the number of bone metastases, sex, age, pathological characteristics, T stage, and N stage (P>0.05).
The findings of this study suggest important clinical implications to detect the concentration of IGFBP-3 in the serum of lung cancer patients so as to evaluate the diagnosis and degree of bone metastasis. Concentration of IGFBP-3 in the serum of bone metastasis patients was positively correlated to concentration of VEGF and MCP-1, which may be highly relevant for the development of new treatments for bone metastasis of lung cancer.
检测并分析可能与骨转移相关的13种细胞因子在非小细胞肺癌（NSCLC）骨转移患者及非骨转移NSCLC患者血清中的情况。
采用Luminex LiquiChip系统检测30例NSCLC骨转移患者及30例非骨转移患者血清中13种可能与骨转移相关的细胞因子浓度。
NSCLC骨转移患者血清中胰岛素样生长因子结合蛋白-3（IGFBP-3）浓度明显高于非骨转移患者（P = 0.014）。两组间其他细胞因子的血清浓度无显著差异（P>0.05）。骨转移组血清中IGFBP-3浓度与血管内皮生长因子（VEGF）浓度呈正相关（r = 0.804，P = 0.009），与单核细胞趋化蛋白1（MCP-1）浓度呈正相关（r = 0.785，P = 0.012），但与其他因素无相关性（P>0.05）。骨转移患者血清中细胞因子浓度之间未发现相关性。骨转移患者血清中IGFBP-3浓度与诊断时是否存在疼痛呈正相关（r = 0.701，P = 0.036），与体能状态（PS）评分呈正相关（r = 0.670，P = 0.048），与骨转移数量、性别、年龄、病理特征、T分期及N分期无相关性（P>0.05）。
本研究结果提示检测肺癌患者血清中IGFBP-3浓度对评估骨转移的诊断及程度具有重要临床意义。骨转移患者血清中IGFBP-3浓度与VEGF和MCP-1浓度呈正相关，这可能与肺癌骨转移新治疗方法的开发高度相关。
